033 821 62 12 endopraxis.noth@hin.ch Spitalweg 1, 3800 Unterseen

Studien

Studienteilnahmen von Dr. med. Daniel Noth als Principal Investigator.

Studienteilnahmen als Principal Investigator

2021

Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study. Diabetes Res Clin Pract. 2021 Aug; 178:108931

doi: 10.1016/j.diabres.2021.108931. Epub 2021 Jul 1

2012

Studie NN9068-3912, Dual II, A trial comparing the efficacy and safety of insulin degludec/liraglutide and insulin degludec in subjects with type 2 diabetes

Publiziert: Diabetes Care 2014; 37(11):2926-2933

2007

Studie NN1998-1390, AERX iDMS (Vergleich inhalierbares Insulin versus Rosiglitazon mit Metformin)

Studie bis jetzt noch nicht publiziert

2005 / 2006

A comparison of efficacy and safety of vildagliptin and gliclazid in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study

Publiziert: Diabetic Medicine 2010, 27:318-326

2005

Three different premixed combinations of biphasic insulin aspart – comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes

Publiziert: Diabetes, Obesity and Metabolism, 2009, 11:700-708

2004

Prospective national multicentre study to assess weight loss and change of HbA1c induced by Xenical and recommended hypocaloric diet in overweight or obese patients with type 2 diabetes in Switzerland

Studie bis jetzt noch nicht publiziert

2003

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial

Publiziert: Lancet 2008; 371:1073-84